TYROSINE KINASE DOMAIN MUTATION IN CHRONIC MYELOID LEUKEMIA AND ITS RESISTANCE TO IMATINIB. A SYSTEMATIC REVIEW

http://doi.org/10.46536/jpumhs/2023/13.03.461

Abstract

The therapy of chronic myeloid leukaemia CML is significantly hampered by the formation of imatinib

resistance in patients, notably as a result of tyrosine kinase domain TKD mutations. The goal of this

systematic review is to provide a thorough analysis of TKD mutations and their connection to imatinib

resistance in CML. To find relevant papers, a comprehensive search approach was used. Then, inclusion

criteria were used to select studies for analysis. Data extraction was carried out to collect pertinent

information on study characteristics, TKD mutations, imatinib resistance, and clinical outcomes after the

risk of bias in the chosen studies was evaluated. The data will be combined numerically and qualitatively,

taking into account any heterogeneity and potential biases within the studies that were included. The goals

of this review are to ascertain the connection between TKD mutations and the emergence of imatinib

resistance in CML and to investigate alternative treatment modalities and their effects on clinical outcomes

in CML patients who have developed imatinib resistance. The results of this study will further our

knowledge of TKD mutations, point out areas that need more research, and provide guidance for the

creation of innovative treatment strategies to overcome imatinib resistance in CM patients. In the end, this

study intends to enhance patient outcomes in the age of targeted medications and contribute to the

optimisation of CML therapy regimens.